NewAmsterdam Pharma Company Forecast, price target & analysts
$22.58
0.70%
Nasdaq, Sep 25, 04:00 pm EDT.
Closed.
Industry
NewAmsterdam Pharma Company Target price 2026 - Analyst rating & recommendation
Powered by
NewAmsterdam Pharma Company Classifications & Recommendation
Buy
91%
Hold
9%
NewAmsterdam Pharma Company Price Target
| Target Price | $53.04 |
| Price | $22.58 |
| Potential |
134.90%
register free of charge
|
| Number of Estimates | 17 |
|
17 Analysts have issued a price target NewAmsterdam Pharma Company 2027 .
The average NewAmsterdam Pharma Company target price is $53.04.
This is
134.90%
register free of charge
$63.00
179.01%
register free of charge
$38.38
69.97%
register free of charge
|
|
| A rating was issued by 23 analysts: 21 Analysts recommend NewAmsterdam Pharma Company to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the NewAmsterdam Pharma Company stock has an average upside potential 2027 of
134.90%
register free of charge
|
Earnings per share, P/E ratio and EV/sales Estimates 2023, 2024 to 2033
Create a premium account to unlock analyst estimates.
Learn more
Powered by
| Dec '22 |
2023 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -4.11 | -2.21 |
| 1,181.58% | 46.23% | |
| P/E | negative | |
| EV/Sales | 174.72 |
Based on analysts' sales estimates for 2023, the NewAmsterdam Pharma Company stock is valued at an EV/Sales of
174.72
unlock
203.65
unlock
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 21.63 | 11.71% |
|---|---|---|
| 2023 |
174.72
707.77%
unlock
|
|
| 2024 |
70.99
59.37%
unlock
|
|
| 2025 |
82.83
16.69%
unlock
|
|
| 2026 |
74.15
10.48%
unlock
|
|
| 2027 |
17.89
75.87%
unlock
|
|
| 2028 |
6.44
64.00%
unlock
|
|
| 2029 |
3.21
50.20%
unlock
|
|
| 2030 |
2.23
30.52%
unlock
|
|
| 2031 |
1.74
21.94%
unlock
|
|
| 2032 |
1.44
17.43%
unlock
|
|
| 2033 |
1.15
19.76%
unlock
|
|
P/S ratio
| Current | 25.21 | 10.21% |
|---|---|---|
| 2023 |
203.65
707.76%
unlock
|
|
| 2024 |
82.74
59.37%
unlock
|
|
| 2025 |
96.55
16.69%
unlock
|
|
| 2026 |
86.43
10.48%
unlock
|
|
| 2027 |
20.86
75.87%
unlock
|
|
| 2028 |
7.51
64.00%
unlock
|
|
| 2029 |
3.74
50.20%
unlock
|
|
| 2030 |
2.60
30.52%
unlock
|
|
| 2031 |
2.03
21.94%
unlock
|
|
| 2032 |
1.67
17.43%
unlock
|
|
| 2033 |
1.34
19.76%
unlock
|
|
NewAmsterdam Pharma Company...
Current NewAmsterdam Pharma Company Upgrades & Downgrades
Create a Premium account to unlock Upgrades/Downgrades.
Learn more
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 08 2026 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Aug 06 2026 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Jun 30 2026 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Feb 19 2026 |
| Needham |
Locked
➜
Locked
|
Locked | Feb 18 2026 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Jan 21 2026 |
| Stifel |
Locked
➜
Locked
|
Locked | Dec 16 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 08 2026 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Aug 06 2026 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Jun 30 2026 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Feb 19 2026 |
|
Locked
Needham:
Locked
➜
Locked
|
Feb 18 2026 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Jan 21 2026 |
|
Locked
Stifel:
Locked
➜
Locked
|
Dec 16 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
